CBD-Rich Extract in Autism: Interview Findings and Standardized Scales Diverged

A randomized autism trial reported improvements on selected interview-based outcomes without significant differences on the standardized ATEC and CARS measures. Both findings belong in any account of the study.

A specific 12-week experiment

Sixty children aged five to eleven received a CBD-rich cannabis extract or placebo under double-blind conditions for 12 weeks. The researchers used interviews as well as the Autism Treatment Evaluation Checklist and Childhood Autism Rating Scale.

The intervention was an extract, not isolated CBD. Its results apply to the tested preparation and population rather than every product labeled cannabis or CBD.

The endpoint determines the conclusion

Reported significant findings included social interaction, anxiety, psychomotor agitation and meals per day. The concentration finding was limited to the mild-ASD subgroup.

The paper did not find significant differences on the ATEC measures or CARS. It would therefore be inaccurate to describe every standardized measure of autism features as improved. Conversely, those null scale comparisons do not erase the separately reported interview findings.

Interpretation requires the entire pattern

Multiple endpoints and subgroup analyses increase the importance of distinguishing the primary question from exploratory comparisons. Different instruments may capture different constructs and may have different sensitivities.

The trial also overlapped the coronavirus pandemic, with participants beginning treatment under different routine conditions. The authors identified this as a limitation. The 12-week period cannot establish long-term developmental safety or durable benefit.

The appropriate conclusion is a qualified, preparation-specific signal on selected outcomes. It does not establish a cure for autism, uniform improvement in core features or a reliable prediction of response for an individual child.

Related analysis

See our analysis of why developmental cannabinoid findings require precise endpoints.

Primary research

Estácio Amaro da Silva Junior and colleagues. Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial. Trends in Psychiatry and Psychotherapy. DOI: 10.47626/2237-6089-2021-0396.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

How Did a Laboratory Study Decide That a Detected Drug Was Non-Prescribed?

A laboratory can identify a drug while relying on outside information to classify its prescription status. A national urine-testing study combined analytical results with medication information supplied by the ordering clinician. Two information streams McClure and colleagues analyzed 231,228 test-result sets from 144,535 patients tested for both opioids and benzodiazepines….

Spread the love

Read Article: How Did a Laboratory Study Decide That a Detected Drug Was Non-Prescribed?

How Did a Stress-Management Trial Protocol Handle Medication Changes?

When a study evaluates psychological treatment, medication changes can complicate attribution of improvement. The 2017 Seren@ctif protocol described how investigators planned to address this issue in a trial of adjustment disorder with anxiety. The planned comparison Servant and colleagues proposed three randomized groups receiving computer-based stress management, an equivalent face-to-face…

Spread the love

Read Article: How Did a Stress-Management Trial Protocol Handle Medication Changes?

What Evidence Supports Extending Lipid Rescue to a Different Poison?

A treatment that appears useful for one toxicant raises a separate scientific question when proposed for another. Eisenkraft and Falk’s 2016 review of lipid emulsion and chemical-agent poisoning provides an example of that evidence gap. Several evidence types The authors discussed proposed lipid-scavenging, metabolic, and cardiovascular mechanisms. They reviewed laboratory…

Spread the love

Read Article: What Evidence Supports Extending Lipid Rescue to a Different Poison?

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us